Invion (ASX:IVX) reports major PhotosoftTM milestones against infectious diseases in the latest quarter

January 31, 2023 12:11 PM AEDT | By Aditi Sarkar
Follow us on Google News:


  • Invion has tabled its December 2022 quarter, highlighting promising research outcomes with PhotosoftTM technology against infectious diseases.
  • In vitro study outcomes indicated PhotosoftTM compounds’ activity against multiple strains of Superbugs.
  • PhotosoftTM compounds also demonstrated antiviral activity against Zika virus, Dengue virus, and the Delta and Omicron BA.1 variants of SARS-CoV-2.
  • The company is targeting to commence at least two Phase 1 trials in 2023.
  • Invion remains well funded to pursue its near- and medium-term development agenda.

Invion Limited (ASX:IVX) is going strong with the development of its PhotosoftTM technology to treat multiple cancers, atherosclerosis and infectious diseases. The ASX-listed company ticked off major milestones during the three-month period ended 31 December 2022.

The life sciences company ended the December quarter with significant strides to prove up its PhotosoftTM technology against infectious diseases, including COVID-19, antibiotic-resistant superbugs and an array of viruses, bacteria and fungi.

Encouraging PhotosoftTM study outcomes against viruses and bacteria

Although cancer is the major focus of PhotosoftTM technology, Invion marked major developments using its technology against viruses and bacteria during the quarter.

One of the major achievements was several PhotosoftTM compounds exhibiting in vitro activity against multiple strains of antibiotic-resistant MRSA bacteria (Superbugs), Escherichia coli bacteria and Candida albicans fungus. This study was conducted by the Australian Centre for Antimicrobial Resistance Ecology (ACARE), University of Adelaide, in partnership with Invion. MRSA is an antibiotic resistant bacteria that is difficult to treat, and various strains of superbugs have been described as one of the top ten threats to humanity by the World Health Organization (WHO). To know more, read here.  

Moreover, in other studies, numerous PhotosoftTM compounds demonstrated antiviral activity against Zika and Dengue viruses. The compounds were more potent than Monensin, the control compound, in both the cases.

Zika virus, found in 86 countries, is linked to birth defects and other neurological complications, while Dengue, nickname “breakbone fever”, causes intense pain in joints and muscles.

© Luciferlucifermetal| Megapixl.com

Prior to the quarter, Invion announced encouraging results from in vitro tests conducted against the Delta and Omicron BA.1 variant of SARS-CoV-2.

Nine of ten PhotosoftTM compounds tested displayed antiviral activity against both variants. Further, the PhotosoftTM compounds were more effective than Remdesivir. Several countries have approved Remdesivir, a broad-spectrum antiviral medication, for emergency use against COVID-19.

Also, some of the compounds had EC50 values that were 250-400 times smaller than Remdesivir. This figure highlighted that the amount required was substantially lower than Remdesivir to achieve the same result.

Read the detailed report here

Human clinical trials expected in CY23

Currently, Invion is gearing up to start human clinical trials in CY23 and is working alongside its research partners, including the Peter MacCallum Cancer Centre. The company has reported encouraging in vitro and in vivo outcomes indicating both safety and efficacy profiles, and across multiple cancer types.

The company targets to begin at least two Phase 1 trials in 2023.

Strong cash position

Invion believes that its strong cash position and its funding agreement with RMW Cho Group will allow the company to carry out its short- and near-term development plans.

Invion shares were trading at AU$0.009 midday on 31 January 2023.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK